



G1 Therapeutics to Ring Nasdaq Stock Market Closing Bell on Wednesday, August 2, 2017

July 27, 2017

RESEARCH TRIANGLE PARK, N.C., July 27, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced that the Company will ring the Nasdaq Stock Market Closing Bell on Wednesday, August 2, 2017, at 4 p.m. EDT, at the Nasdaq MarketSite in New York City.

The bell ringing will celebrate G1's May 17, 2017, initial public offering and listing on the Nasdaq Global Select Market. G1 employees will join Chief Executive Officer Mark Velleca, MD, PhD, as he performs the honorary closing bell ringing ceremony.

"G1's listing on the Nasdaq is a significant corporate milestone, and we're honored to be invited by Nasdaq to celebrate the hard work that enabled us to become a publicly traded company," said Velleca. "Since our first round of funding four years ago, G1 has grown from a small group of scientists to more than 35 team members dedicated to developing new and improved therapies for the treatment of cancer. Our public offering will enable us to advance our clinical development programs and expand our pipeline of innovative therapies to address unmet needs in patients with cancer."

A live webcast of the ceremony will begin at 3:45 p.m. EDT and be available at: <https://new.livestream.com/nasdaq/live>.

About Nasdaq

Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 89 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to 3,800 total listings with a market value of \$11 trillion. To learn more, visit: <http://business.nasdaq.com>.

About G1 Therapeutics, Inc.

G1 Therapeutics (GTHX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer. G1's two clinical assets, trilaciclib and G1T38, are CDK4/6 inhibitors, a validated and promising class of targets for anti-cancer therapeutics. Trilaciclib and G1T38 have broad therapeutic potential in many forms of cancer and may serve as the backbone of multiple combination regimens. In addition, G1 is advancing G1T48, a potential first/best-in-class oral selective estrogen receptor degrader, or SERD, which is targeted for the treatment of ER+ breast cancer.

G1 is based in Research Triangle Park, NC. For additional information about G1, please visit www.g1therapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on G1 Therapeutics' expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause G1 Therapeutics' actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in G1 Therapeutics' filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, G1 Therapeutics assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Contacts:

Investors:

Robert Uhl

Westwicke Partners

858-356-5932

robert.uhl@westwicke.com

Media:

Laura Bagby

6 Degrees Communications

312-448-8098

lbagby@6degreespr.com



G1 Therapeutics